RemeGen Co Stock

RemeGen Co Debt

The Debt of RemeGen Co (9995.HK) as of Aug 7, 2026 is -277.88 M CNY. In the previous year, Debt was 1.80 B CNY — a change of -115.45% (lower).

Debt

-277.88 MCNY

YoY

-115.45%

Last updated:

In 2026, RemeGen Co's total debt was -277.88 M CNY, a -115.45% change from the 1.80 B CNY total debt recorded in the previous year.

Access this data via the Eulerpool API

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd is a Chinese biotechnology company based in Yantai. The company was founded in 2008 by Dr. Li Zhu, who also developed the company's main product. RemeGen's goal is to develop innovative therapies for the treatment of cancer and autoimmune diseases. The company's business model involves researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. RemeGen works closely with leading researchers from around the world and conducts clinical trials to assess the safety and efficacy of its products. The company has various divisions focused on developing drugs for different diseases, including oncology, autoimmune diseases, and dermatology. RemeGen's flagship product is the antibody FGFR4, which is a new therapeutic agent for treating liver cancer. FGFR4 is one of the most highly expressed genes in liver cancer cells and plays a crucial role in tumor progression. The antibody inhibits the activity of FGFR4, thereby preventing the growth of liver cancer cells. Clinical studies have shown FGFR4 to be a promising treatment option for liver cancer, with positive results. In addition to FGFR4, RemeGen has other promising products in its development pipeline, including the antibody RC48, which is used in the treatment of advanced or metastatic lung cancer. RC48 targets the Epidermal Growth Factor Receptor (EGFR), a protein that is highly upregulated in many types of cancer and promotes the growth of cancer cells. Clinical studies have shown RC48 to be a promising treatment option for lung cancer, reaching Phase III. Overall, RemeGen Co Ltd has a promising approach to developing innovative drugs that have the potential to change the standard of care in oncology, autoimmune diseases, and dermatology. Through close collaboration with leading researchers and clinical trials, the company is well-positioned to further develop its pipeline and improve medical care for patients in China and worldwide. Answer: RemeGen Co Ltd is a Chinese biotechnology company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. It has a business model of researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. The company's divisions focus on oncology, autoimmune diseases, and dermatology. Its flagship product is the antibody FGFR4, which is used for treating liver cancer. RemeGen also has other promising products, such as the antibody RC48 for advanced lung cancer. The company's approach has the potential to change the standard of care in these medical fields. RemeGen Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding RemeGen Co's Debt Structure

RemeGen Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing RemeGen Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to RemeGen Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in RemeGen Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about RemeGen Co stock

Debt of RemeGen Co is -277.88 M CNY in 2026.

Debt of RemeGen Co changed from 1.80 B CNY to -277.88 M CNY, representing a -115.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's RemeGen Co historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — RemeGen Co

All Key Metrics — RemeGen Co